The United Kingdom and the United States have agreed to a landmark commercial pact that will keep no import taxes on UK drug products being sold in the American market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to raise expenditure on drugs through the public health system. This move ensures that tariffs on these key products will remain at nothing for a duration of three years.
This development is in response to recent threats to hike tariffs on branded pharmaceutical imports, with figures discussed as high as 100%.
"This agreement between the UK reinforces the worldwide climate for innovative medicines and establishes much-needed fairness to American-British medicine commerce," a statement declared.
Commercial Impact
Pharmaceuticals are one of the UK's most significant goods shipped to the America, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount accounted for nearly one-fifth of British export trade in that span.
"This guarantee secures employment, boosts investment and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister stated.
Key British Pledges
The agreement involves several key changes from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to double overall NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds topped twenty percent.
Broader Context
This agreement comes amid a ongoing row between the drug companies and the ministers over drug pricing and NHS adoption.
These tensions were intensified by assertions that US customers were charged several times more for the same drugs than patients in the other developed nations.
In recent months, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had decreased as a percentage of its resources over the previous ten-year period.
